🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Congratulations Jeff Yang MD FACS on your well deserved recognition by IASLC w the Cliff Mountain staging award. Your lecture meaningfully demonstrated how staging is a language we share w each other, with patients and with the public. You and ALCSI are inspiring a generation!

Dr. Geoffrey Liu presents data from TRUST-II, global phase II trial evaluating next-gen ROS1 TKI taletrectinib in patients with ROS1 NSCLC. PFS data - esp in 1L setting - awaited. Looking forward to additional data to be shared next week at ESMO. #WCLC24 The ROS1ders, Inc. IASLC

Dr. Tony Mok shares additional insights from CROWN, on pts w/ ALK+ nsclc who progressed early vs late on 1L lorlatinib, subsequent therapies. Critical to have these updates as the follow-up increases. #WCLC24 IASLC ALK Positive ALK+ International

Helpful and highly clinically relevant insights presented by Dr. Todd Bauer on the kinetics and management of AEs on 1L lorlatinib in the CROWN trial. Continued updates important for patients, caregivers, clinicians. #WCLC24 IASLC ALK Positive ALK+ International

1/4 Alright, so here are my thoughts on Radiation to Residual Disease after Targeted Therapies as presented at #WCLC24. Focusing on EGFR mutant #lungcancer where we all agree, I think, that osimertinib alone cannot be the answer, right⁉️🧐 The main risk here is secondary

We are excited to share the updated efficacy&safety data of #Zidesamtinib (NVL-520), a next-generation ROS1-selective, TRK-sparing, brain-penetrant inhibitor in ROS1 fusion+ solid tumors, from the ongoing #ARROS1 global phase 1/2 trial, presented today #ESMO24 by Benjamin Besse

Nice of Journal of Clinical Oncology to publish this acknowledgment of reviewers for 2024. The peer review process is not perfect - it takes a lot of time to properly review submitted manuscripts and this is uncompensated time. But I think there are real benefits - individually and to the field.

Stage III ALK+ NSCLC: consolidation ALK TKI v Durva v Obs JTO & JTO CRR: -67pts, ALKi=15 Durva=30 obs=22 -mrwPFS favors ALKi (NR, 95%CI 22.7-NR) v durva (11.3m HR 0.12 p=0.006) v obs (7.2m HR=0.04 p<0.0001) Small n, but useful OncoAlert Amin Nassar, MD #LCSM jto.org/article/S1556-…

Dr. Sarah Waliany, MD, MS is one of our abstract award winners for the DF/HCC lung cancer symposium - she discussed mechanisms of resistance to first-line vs. later-line Alectinib for ALK + NSCLC ALK Positive ALK+ International JessicaJLinMD Lecia Sequist, MD, MPH

Tackling big problems requires radical collaboration 💪. The “PoweRD 2 Cure” team strives to overcome minimal residual disease (MRD) observed with #targetedtherapy in #lungcancer. Powerhouse team to conquer an urgent, unmet clinical question. Break Through Cancer ALK Positive

Despite progress, advanced ALK+ lung cancer almost always recurs. By deeply exploring the biology of cancer cells that resist treatment, the new PoweRD 2 Cure ALK+ Lung Cancer TeamLab aims to bend the survival curve for patients - JessicaJLinMD #RadicalCollaboration